Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced that its representatives will participate in the IPAC-RS 2026 Nasal Innovation Forum. The event is scheduled for September 16-17, 2026, in Jersey City, New Jersey. This forum provides a platform for leaders in nasal drug development to discuss innovations and challenges in the field.
Eric Weisblum, CEO of Silo Pharma, emphasized the importance of this engagement, stating that the forum offers a valuable opportunity to collaborate with experts in nasal drug delivery as the company advances SPC-15, its investigational therapy for post-traumatic stress disorder (PTSD). SPC-15 utilizes a novel nose-to-brain approach, which aims to deliver the drug directly to the central nervous system, potentially improving efficacy and reducing systemic side effects compared to traditional delivery methods.
The company recently reported encouraging preclinical data for SPC-15. The formulation and its delivery device met predefined specifications for assay, impurities, pH, and microbiological quality over a nine-month period. Additionally, six-month accelerated stability data were consistent and aligned with long-term stability findings. These results suggest that SPC-15 is stable and suitable for further development, supporting its progression toward clinical trials.
The participation in the IPAC-RS forum is part of Silo Pharma's broader strategy to develop innovative treatments for underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. The company's pipeline includes SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo collaborates with leading universities and laboratories to advance its research.
This announcement is significant for investors and the medical community as it highlights Silo Pharma's active efforts to bring SPC-15 to market. PTSD is a debilitating condition affecting millions worldwide, and current treatments often have limited efficacy and significant side effects. A novel nose-to-brain delivery system could offer a new therapeutic option, potentially improving patient outcomes. The stability data provided are a critical step in regulatory approval, and the company's engagement with industry experts at the forum may facilitate partnerships and insights that accelerate development.
For more information about Silo Pharma and its pipeline, visit the company's website at silopharma.com. The latest news and updates on SILO are available in the company's newsroom at https://ibn.fm/SILO.
